AMENDMENT NO. 5 TO TESTING AND SERVICES AGREEMENTTesting and Services Agreement • April 1st, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances
NOW THEREFORE, in consideration of the mutual agreements contained herein, the parties agree the TSA is hereby amended as follows:
AMENDMENT NO. 3 TO TESTING AND SERVICES AGREEMENTTesting and Services Agreement • March 6th, 2018 • Vermillion, Inc. • In vitro & in vivo diagnostic substances
THIS AMENDMENT NO. 3 TO TESTING AND SERVICES AGREEMENT (this “Amendment”) is made and entered into as of the date on which both parties have executed this Amendment (the “Amendment Effective Date”) by and between Quest Diagnostics Incorporated, a Delaware corporation (“Quest Diagnostics”) on the one hand, and Vermillion, Inc., a Delaware corporation and ASPiRA Labs, a Delaware corporation and wholly owned subsidiary of Vermillion, Inc. (collectively “Vermillion”) on the other hand, with respect to that certain Testing and Services Agreement dated as of March 11, 2015, and that certain Amendment No. 1 to Testing and Services Agreement dated as of April 10, 2015 and that certain Amendment No. 2 to Testing and Services Agreement dated as of March 11, 2017 (together, the “TSA”). Capitalized terms used and not otherwise defined herein are used with the meanings attributed to them in the TSA. All references to section numbers refer to section numbers in the TSA.
TESTING AND SERVICES AGREEMENTTesting and Services Agreement • April 19th, 2022 • Utah
WHEREAS, Sponsor is desirous of obtaining testing and evaluation services that (a) require use of unique or special University facilities, that either do not exist elsewhere or are not readily accessible; and (b) involve established, pre-existing methods of a primarily technical nature; and
AMENDMENT NO. 4 TO TESTING AND SERVICES AGREEMENTTesting and Services Agreement • March 17th, 2020 • Vermillion, Inc. • In vitro & in vivo diagnostic substances
THIS AMENDMENT NO. 4 TO TESTING AND SERVICES AGREEMENT (this “Amendment”) is made and entered into as of the date on which both parties have executed this Amendment (the “Amendment Effective Date”) by and between Quest Diagnostics Incorporated, a Delaware corporation (“Quest Diagnostics”) on the one hand, and Vermillion, Inc., a Delaware corporation and ASPiRA Labs, a Delaware corporation and wholly owned subsidiary of Vermillion, Inc. (collectively “Vermillion”) on the other hand, with respect to that certain Testing and Services Agreement dated as of March 11, 2015, and that certain Amendment No. 1 to Testing and Services Agreement dated as of April 10, 2015 and that certain Amendment No. 2 to Testing and Services Agreement dated as of March 11, 2017 and that certain Amendment No. 3 to Testing and Services Agreement dated as of January 19, 2019 (together, the “TSA”). Capitalized terms used and not otherwise defined herein are used with the meanings attributed to them in the TSA. All r
TESTING AND SERVICES AGREEMENTTesting and Services Agreement • May 12th, 2015 • Vermillion, Inc. • In vitro & in vivo diagnostic substances • New Jersey
THIS TESTING AND SERVICES AGREEMENT (“Agreement”) is made and entered into as of March 11, 2015 (the “Effective Date”), by and between Vermillion, Inc., a Delaware corporation (formerly known as Ciphergen Biosystems, Inc.), and ASPiRA Labs, a Delaware corporation and wholly owned subsidiary of Vermillion, Inc. (collectively “Vermillion”) on the one hand and Quest Diagnostics Incorporated, a Delaware corporation, (“Quest” or “Quest Diagnostics”) on the other hand. Vermillion and Quest Diagnostics are sometimes individually referred to herein as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 2 TO TESTING AND SERVICES AGREEMENTTesting and Services Agreement • March 13th, 2017 • Vermillion, Inc. • In vitro & in vivo diagnostic substances
THIS AMENDMENT NO. 2 TO TESTING AND SERVICES AGREEMENT (this “Amendment”) is made and entered into as of this 1st day of March, and effective March 11, 2017 or any other date mutually agreed by the Parties (the “Amendment Effective Date”) by and between Quest Diagnostics Incorporated, a Delaware corporation (“Quest Diagnostics”) on the one hand, and Vermillion, Inc., a Delaware corporation and ASPiRA Labs, a Delaware corporation and wholly owned subsidiary of Vermillion, Inc. (collectively “Vermillion”) on the other hand, with respect to that certain Testing and Services Agreement dated as of March 11, 2015, and that certain Amendment No. 1 to Testing and Services Agreement dated as of April 10, 2015 (together, the “TSA”). Capitalized terms used and not otherwise defined herein are used with the meanings attributed to them in the TSA. All references to section numbers refer to section numbers in the TSA.
